title: Extrathymic development and function of human T-lymphocytes from bone marrow cells in vitro.
abstract: To enrich low-density human bone marrow (BM) cells for putative progenitors of T-lymphocytes, CD7+ CD3- cells were sorted (purity was estimated at > 99.9%) and cultured under limiting dilution conditions with irradiated allogeneic stimulator cells, interleukin (IL) 2, and PHA. Clonal populations were available for analysis from Day 25 onward. By this time, all clones (n = 54) expressed CD3 and alpha/beta-T cell receptor (TCR2). Fifty percent of the clones were CD4+ and 50% were CD8+, with no double positives, whereas almost all clones obtained under identical conditions from peripheral blood (PB) cells were CD4+. All clones were capable of autocrine proliferation, which was blocked by CD25 or CD71 mAb. Most or all clones tested (n = 15) responded to IL 4 and IL 7 as well as IL 2, but not to IL 3 or GM-CSF and only two responded to IL 9. Most clones accumulated mRNA for GM-CSF, IL 2, IL 3, IL 4, IL 5 and also IL 9, but 6 of 11 were negative for IFN-gamma mRNA, and all were negative for IL 6 mRNA. Sixty-two percent of CD4+ and 85% of CD8+ clones (total 70% of all clones) mediated lectin-dependent cell lysis; but whereas 35% of CD4+ and 65% of CD8+ clones (total 46% of all clones) lysed K562 natural killer (NK)-susceptible targets, only 24% of CD4+ and 5% of CD8+ clones (total 17% of all clones) killed lymphokine-activated killer (LAK)-susceptible Daudi cells. Only three clones lysed allogeneic LCL targets and none lysed autologous targets. Furthermore, none of the clones proliferated when stimulated by autologous cells, neither did they suppress proliferative responses of autologous cells. These results suggest that CD3- cells from the bone marrow can acquire functional cytotoxic and proliferative programs extrathymically during in vitro culture with IL 2, mitogens and allogeneic cells, but do not manifest autoreactivity in the three test systems, cytotoxicity, suppression, or autocrine proliferation.
authors.affiliation: Medical and Natural Sciences Research Center, University of Tübingen, Federal Republic of Germany.
authors.forename: M
authors.initials: M
authors.lastname: Adibzadeh
authors.forename: H J
authors.initials: HJ
authors.lastname: Bühring
authors.forename: T
authors.initials: T
authors.lastname: Daikeler
authors.forename: P
authors.initials: P
authors.lastname: Siegels-Hübenthal
authors.forename: M
authors.initials: M
authors.lastname: Owsianowsky
authors.forename: A
authors.initials: A
authors.lastname: Schenk
authors.forename: A
authors.initials: A
authors.lastname: Rehbein
authors.forename: K
authors.initials: K
authors.lastname: Schaudt
authors.forename: E
authors.initials: E
authors.lastname: Schlotz
authors.forename: H
authors.initials: H
authors.lastname: Pohla
mesh_terms: D000945:Antigens, Differentiation, T-Lymphocyte / Q000235:genetics / Q000378:metabolism; D001483:Base Sequence; D001853:Bone Marrow / Q000276:immunology*; D001854:Bone Marrow Cells; D002454:Cell Differentiation; D002469:Cell Separation; D002999:Clone Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008934:Mitogens / Q000494:pharmacology; D008969:Molecular Sequence Data; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D016207:Cytokines; D017931:DNA Primers; D008934:Mitogens; D012333:RNA, Messenger